Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Retained Earnings (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Retained Earnings for 7 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 11.72% year-over-year to $2.6 million, compared with a TTM value of $2.6 million through Dec 2025, down 11.72%, and an annual FY2025 reading of $2.6 million, down 11.72% over the prior year.
  • Retained Earnings was $2.6 million for Q4 2025 at Avidity Biosciences, up from -$1.3 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $2.9 million in Q4 2024 and bottomed at -$1.3 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$327.5 million, with a median of -$167.7 million recorded in 2021.
  • The sharpest move saw Retained Earnings tumbled 346200.0% in 2022, then surged 2221.6% in 2024.
  • Year by year, Retained Earnings stood at -$187000.0 in 2021, then crashed by 1342.78% to -$2.7 million in 2022, then skyrocketed by 104.63% to $125000.0 in 2023, then soared by 2221.6% to $2.9 million in 2024, then decreased by 11.72% to $2.6 million in 2025.
  • Business Quant data shows Retained Earnings for RNA at $2.6 million in Q4 2025, -$1.3 billion in Q3 2025, and $1.8 million in Q2 2025.